Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biotech-beach crawled date : 2022 - 11 - 03 save search
Puma Biotechnology Reports Third Quarter 2022 Financial Results
Published: 2022-11-03 (Crawled : 23:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.91%
H: 0.92%
C: 0.77%
PBYI | $5.01 0.4% 0.4% 290K
|
Health Technology
|
| O: 0.0%
H: 1.85%
C: -0.93%
financial results
Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates
Published: 2022-11-03 (Crawled : 23:00) - biospace.com/
CRDF | $4.34 -0.69% -0.69% 610K
|
Health Services
|
| O: 0.0%
H: 1.01%
C: -4.7%
results
Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition
Published: 2022-11-03 (Crawled : 19:00) - biospace.com/
PSTX | $2.02 1.0% 0.99% 640K
|
Health Technology
|
| O: -0.52%
H: 7.63%
C: 6.84%
fviii-101 meeting therapeutics presentation therapy
Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting
Published: 2022-11-03 (Crawled : 19:00) - biospace.com/
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: -0.09%
H: 2.71%
C: 1.77%
ingrezza meeting in vitro
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition
Published: 2022-11-03 (Crawled : 15:00) - biospace.com/
GRCL | $10.25 -0.29% 6.4M
|
Manufacturing
|
| O: -1.52%
H: 25.31%
C: 12.35%
gc012 meeting
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.84%
H: 1.99%
C: -0.4%
meeting study phase 1
Vaxcyte to Present at Upcoming Investor Conferences
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
PCVX | $60.82 0.33% 0.33% 1.3M
|
Health Technology
|
| O: -0.07%
H: 6.9%
C: 5.48%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: -1.23%
H: 7.61%
C: 1.94%
Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call
Published: 2022-11-03 (Crawled : 13:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: -2.07%
H: 1.41%
C: -3.52%
conference therapeutics financial
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022
Published: 2022-11-03 (Crawled : 13:00) - biospace.com/
LCTX | $1.15 -4.17% 0.0% 1.1M
|
Health Technology
|
| O: 0.0%
H: 5.38%
C: 1.54%
report therapeutics financial update results
Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit
Published: 2022-11-03 (Crawled : 13:00) - biospace.com/
EQ | $1.63 -5.78% -6.13% 100K
|
Health Technology
|
| O: -2.31%
H: 1.78%
C: 1.18%
drug presentation
Aadi Bioscience to Present at Upcoming Investor Conferences
Published: 2022-11-03 (Crawled : 13:00) - biospace.com/
AADI | $1.835 1.94% 1.91% 140K
|
Manufacturing
|
| O: -1.61%
H: 4.49%
C: 2.21%
bioscience
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Published: 2022-11-03 (Crawled : 13:00) - biospace.com/
LBPH | $17.48 -2.94% -3.03% 520K
|
Manufacturing
|
| O: 1.06%
H: 23.04%
C: 7.33%
pharmaceuticals financial update results
Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022
Published: 2022-11-03 (Crawled : 13:00) - biospace.com/
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: -0.09%
H: 2.71%
C: 1.77%
huntington disease study huntington’s disease
New Report from GoodRx Shows Positive Impact of Giving Pharmacists the Power to Prescribe
Published: 2022-11-03 (Crawled : 12:00) - biospace.com/
GDRX 4 | $6.69 -0.59% -0.6% 640K
|
Technology Services
|
| O: -1.6%
H: 0.81%
C: -0.41%
report impact positive
Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference
Published: 2022-11-02 (Crawled : 00:00) - biospace.com/
CDMO | $6.41 -1.69% -1.72% 790K
|
Health Technology
|
| O: -0.51%
H: 3.16%
C: -2.81%
conference
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
Published: 2022-11-02 (Crawled : 00:00) - biospace.com/
ACAD | $16.82 -1.47% -1.49% 3.5M
|
Health Technology
|
| O: -1.2%
H: 7.08%
C: 1.66%
pharmaceuticals financial results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.